Literature DB >> 8841737

The implications of noncompliance with antihypertensive medication.

B Girvin1, G D Johnston.   

Abstract

Given the clear evidence that reducing blood pressure decreases the vascular complications of hypertension, loss of efficacy represents the principal complication of noncompliance with antihypertensive therapy. Withdrawal symptoms are also important and occur after abruptly stopping beta-blockers and centrally-acting antihypertensive drugs. Very few studies have been conducted to assess the impact of missing 1 or 2 doses of an antihypertensive agent on short term control of blood pressure. A high trough to peak ratio (> 50%) for a once-daily medication suggests a long duration of action. However, methodological problems in the design of the studies to determine trough to peak ratios make comparisons between various medications very difficult. In general, however, stopping a drug with a low through to peak ratio is more likely to result in loss of antihypertensive effect than a drug with a high ratio. Poor compliance in dose-escalating studies with antihypertensive agents may have resulted in excessively high dose recommendations in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841737     DOI: 10.2165/00003495-199652020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  66 in total

Review 1.  The abrupt discontinuation of antihypertensive treatment.

Authors:  S B Garbus; M A Weber; R T Priest; D D Brewer; F A Hubbell
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

2.  Predictability of antihypertensive responsiveness and alpha-adrenoceptor antagonism during prazosin treatment.

Authors:  H L Elliott; R Donnelly; P A Meredith; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

3.  Patient compliance for antihypertensive medication: the usefulness of urine assays.

Authors:  D T Lowenthal; W A Briggs; R Mutterperl; B Adelman; M A Creditor
Journal:  Curr Ther Res Clin Exp       Date:  1976-03

Review 4.  Therapeutic coverage: reducing the risks of partial compliance.

Authors:  P A Meredith; H L Elliott
Journal:  Br J Clin Pract Suppl       Date:  1994-05

5.  Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration.

Authors:  G Leonetti; L Terzoli; C Bianchini; C Sala; A Zanchetti
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

6.  Coronary artery syndromes after sudden propranolol withdrawal.

Authors:  E L Alderman; D J Coltart; G E Wettach; D C Harrison
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

8.  Improved compliance measures: applications in an ambulatory hypertensive drug trial.

Authors:  P Rudd; S Ahmed; V Zachary; C Barton; D Bonduelle
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

9.  Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.

Authors:  M G Myers
Journal:  J Hypertens Suppl       Date:  1994-11

10.  Measuring patient compliance in antihypertensive therapy--some methodological aspects.

Authors:  H Enlund
Journal:  J Clin Hosp Pharm       Date:  1982-03
View more
  4 in total

Review 1.  Assessing medication adherence in the elderly: which tools to use in clinical practice?

Authors:  Eric J MacLaughlin; Cynthia L Raehl; Angela K Treadway; Teresa L Sterling; Dennis P Zoller; Chester A Bond
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Eprosartan: a review of its use in the management of hypertension.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 3.  Eprosartan: a review of its use in the management of hypertension.

Authors:  Gayle W Robins; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.